AbbVie Says Humira's Many Patents Is No Antitrust Violation

By Matt Bernardini · October 15, 2019, 5:37 PM EDT

AbbVie and several other drugmakers have asked an Illinois federal court to dismiss a sweeping proposed class action accusing the company of illegally shielding its immunosuppressant Humira from competition with a "patent...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Memorandum

Case Information

Case Title

In Re: Humira (Adalimumab) Antitrust Litigation

Case Number

Court

Illinois Northern

Nature of Suit

410(Anti-Trust)

Date Filed

March 18, 2019

Recent Articles By Matt

November 26, 2019
AbbVie Says AndroGel Suit Should Be Moved To Georgia
October 18, 2019
Ill. City Ran To Court In Discovery Row, Express Scripts Says
October 09, 2019
Fresenius To Pay $5M To Resolve Mass. Medicare Fraud
October 08, 2019
Calif. Becomes 1st State To Target 'Pay-For-Delay' Drug Deals
September 26, 2019
Gov't Backs SmileDirect In Ga. Dental Board Members' Appeal
September 26, 2019
Certification Board Escapes Doctors' Antitrust Suit
September 18, 2019
FCC Links Lifeline, Medicaid Program Enrollment
September 08, 2019
Congress Pressed To Renew Funding For Rape Kit Testing
August 30, 2019
FCC Trying To Mitigate Mexican Spectrum Interference
August 26, 2019
FTC Fights E-Prescription Co. Bid To Nix Monopoly Case